Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere (Docetaxel) Plus Vectibix (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study.

Trial Profile

Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere (Docetaxel) Plus Vectibix (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2014

At a glance

  • Drugs Panitumumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms TVA
  • Most Recent Events

    • 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 28 Jun 2012 Companies added in the association field as reported by EudraCT.
    • 18 Jan 2012 Actual patient number (62) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top